ArticleAIDS (London, England)2025
Interest and disparities in awareness and uptake of doxycycline postexposure prophylaxis among US MSM with HIV.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perceptions of DoxyPEP use Among Racial & Ethnic Minority Patients.Journal of racial and ethnic health disparities · 2026Article
- Early Implementation of Doxycycline Postexposure Prophylaxis at an Infectious Diseases Clinic in the Southern United States.AIDS patient care and STDs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThe CDC recommends doxycycline postexposure prophylaxis (doxyPEP) for MSM with a bacterial sexually transmitted infection (bSTI) in the past year. This study explored determinants of doxyPEP awareness and uptake, and associations with HIV care outcomes, among US MSM with HIV.
designCross-sectional study.
methodsFrom October 2023 to October 2024, we enrolled 827 MSM with HIV from 46 states, Washington, DC, and Puerto Rico via a popular geospatial networking app. Adjusted multivariable logistic regression examined determinants of doxyPEP awareness/use and associations with HIV treatment adherence, viral suppression, and care engagement.
resultsAmong 827 participants, 13% were currently taking doxyPEP, 46% were aware of doxyPEP but not prescribed it, and 41% had not heard of it. Of 360 participants Centers for Disease Control and Prevention (CDC)-eligible for doxyPEP, 20% were prescribed it, 49% had heard of it but were not on it, and 31% were unaware, 95% of whom expressed interest. Neither awareness nor use of doxyPEP was associated with HIV care outcomes. Both awareness and uptake of doxyPEP were higher among participants with a recent bSTI [adjusted odds ratio (aOR) = 1.15, 95% confidence interval (CI): 1.06-1.25; aOR = 1.11, 95% CI: 1.05-1.17, respectively) and lower in the United States. Midwest, Mountain, and South regions [inverse-variance weighted average (IVW-Avg) aOR = 0.81, 95% CI: 0.76-0.86; IVW-Avg aOR = 0.86, 95% CI: 0.82-0.90, respectively] relative to Pacific states.
conclusionHigh doxyPEP interest underscores unmet demand in integrated HIV/sexual healthcare. Sociodemographic and geographic disparities in doxyPEP implementation necessitate targeted interventions for MSM with HIV to optimize impact on the bSTI epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.